Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Life Sciences to Acquire NovaScreen Biosciences for Up to $30M in Stock and Cash

NEW YORK, Sept. 8 (GenomeWeb News) - Caliper Life Sciences plans to acquire NovaScreen Biosciences, a screening, profiling, and assay development-services company for up to $30 million in stock and cash, Caliper said today.


Under the agreement, Caliper will purchase Hanover, Md.-based NovaScreen for $22 million, subject to certain financial parameters, and up to an additional $8 million, depending on revenue milestones over the next 30 months. Eighty percent of the payments will be made in Caliper common stock and 20 percent in cash.


The transaction is due to close during the fourth quarter, and Caliper expects NovaScreen to contribute approximately $2 million to its revenues.


NovaScreen focuses on in vitro screening assays and in silico predictive screening tools, with particular expertise in receptor pharmacology.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.